Surf Bio Appoints Industry Veteran Doug Hecker as Head of Technical Operations

Brings 30+ Years of CMC Expertise to Advance High-Concentration Biologic Delivery

PALO ALTO, Calif., March 14, 2025 /PRNewswire/ -- Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today the appointment of Doug Hecker as Head of Technical Operations. With over 30 years of experience in chemistry, manufacturing, and controls (CMC), Hecker has been instrumental in developing and commercializing novel excipients, spray-dried formulations, drug substances, and drug products. His expertise in spray drying, GMP compliance, and commercial-scale drug product manufacturing will drive the advancement of Surf Bio's SnapShot™ platform, enabling subcutaneous administration of high-dose biologics.

Hecker has a distinguished track record of establishing and optimizing commercial-scale manufacturing for innovative drug delivery technologies. Notably, he played a key role in bringing Captisol® to market, a novel excipient that has become a cornerstone in enabling advanced drug formulations. Following this success, he led strategic growth initiatives at Hovione, helping establish the company as a global leader in pharmaceutical spray drying. Most recently, Hecker served as Vice President, Drug Delivery Technologies at Davos Pharma, where he led technical business development, technology transfer, and commercialization strategies.

"Doug's expertise in excipient development, spray drying, and large-scale drug product manufacturing makes him an invaluable addition to the Surf Bio team," said Bryan Mazlish, CEO of Surf Bio. "His leadership will be instrumental in scaling the SnapShot platform, accelerating our path to clinical studies, and deepening commercial collaborations with leading biopharmaceutical companies."

Hecker's extensive experience in cGMP manufacturing, FDA regulatory compliance, and technology transfer positions him to drive Surf Bio's commercial rollout forward. His insights will enable Surf Bio to rapidly scale the SnapShot platform to enhance the access and convenience of biologic drug delivery by bringing high-dose subcutaneous formulations to market.

"The rapid growth of biologics is creating an urgent need for scalable, high-dose, subcutaneous delivery solutions," said Doug Hecker, Head of Technical Operations at Surf Bio. "I'm excited to leverage my expertise to advance the company's manufacturing capabilities and support its efforts to transform biologic drug delivery."

About Surf Bio:
Surf Bio is a biopharmaceutical company transforming the delivery of antibodies and biologics via its SnapShot™ technology platform.  Powered by the Company's proprietary polymer, SnapShot enables the development of ultra-high concentration formulations of monoclonal antibodies (mAbs) and biologics that can be administered using a single, standard autoinjector shot.  To date, in-vitro and in-vivo safety and efficacy data have demonstrated that SnapShot enables drug developers to produce very high concentration, subcutaneous formulations of novel mAbs and biologics. Surf Bio was launched by the founders of Bigfoot Biomedical and AGC to commercialize a breakthrough drug delivery technology developed in the Appel lab at Stanford University. For more information about Surf Bio, visit www.surf.bio.

Contact for Surf Bio:
Tiberend Strategic Advisors, Inc.
Eric Reiss
[email protected]

SOURCE Surf Bio, Inc.